First-in-class Therapeutic Against Urinary Retention (Continence) in Patients with Chronic Spinal Cord Injury and Related Disorders

针对慢性脊髓损伤及相关疾病患者尿潴留（失禁）的一流疗法

• 批准号: 240662
• 负责人: Guertin Pierre
• 金额: $ 11.66万
• 依托单位: Centre hospitalier de l'Universit Laval (Qubec)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2011
• 资助国家: 加拿大
• 起止时间: 2011-09-01 至 2012-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=240662&lang=en
• 关键词: Animal Model; Behavioral Assessment; Chronic Treatment; First-In-Class Drug Treatment; Multibillion Dollars Market; Pharmacological Approach; Spinal Cord Injury; Spinal Micturition Center; Urinary Retention

The number of patients currently living with a spinal cord injury (SCI) has importantly increased in recent years. In fact, SCI (1.3 M) has become the second most common neurological problem in North America after Alzheimer (4 M). No cure that can repair

近年来，目前生活在脊髓损伤(SCI)中的患者数量显著增加。事实上，脊髓损伤(1.3M)已经成为北美仅次于阿尔茨海默氏症(4M)的第二大最常见的神经问题。没有可以修复的解药